Alan Keith Boyd
Chief Executive Officer at Alan Boyd Consultants Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Kenna | M | - |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland.
The Royal College of Physicians
| - |
Nicholas Mark Barnes | M | - |
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | 20 years |
John Gordon | M | - |
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | 20 years |
Catherine A. Brady | M | - |
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | - |
Jane G. Farrar | M | - |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
Sarah L. Cole | M | - |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 5 years |
Warren Cooper | M | 71 |
The Royal College of Physicians
| - |
Richard Bryce | M | 66 |
The Royal College of Physicians
| - |
Vincent O'Neill | M | 55 |
The Royal College of Physicians
| - |
Abdur Rahman Khan | M | 90 |
The Royal College of Physicians
| - |
Kei Siong Khoo | M | 62 |
The Royal College of Physicians
| - |
Peng Tiam Ang | M | 65 |
The Royal College of Physicians
| - |
Andrew Richard Rut | M | 63 |
The Royal College of Physicians
| - |
Sanjay Rajpara | M | - |
The Royal College of Physicians
| - |
Kevin Chen | M | - |
The Royal College of Physicians
| - |
Christian Billy Jung | M | 42 |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 4 years |
Matt Gysler | M | - |
The Royal College of Physicians
| - |
Magnus Jaderberg | M | - |
The Royal College of Physicians
| - |
Brian John O’Keeffe | M | - |
The Royal College of Physicians
| - |
Christopher Ball | M | - |
The Royal College of Physicians
| - |
Curt Mikael von Euler-Chelpin | M | 71 |
The Royal College of Physicians
| - |
Tong Choon Cheo | M | 78 |
The Royal College of Physicians
| - |
Olor'ogun Sonny Folorunso Kuku | M | 80 |
The Royal College of Physicians
| - |
David J. Clark | M | 59 |
The Royal College of Physicians
| - |
Suyash Prasad | M | 54 |
The Royal College of Physicians
| - |
Pyarelal Baburam Tiwari | M | 77 |
The Royal College of Physicians
| - |
Athasit Vejjajiva | M | 88 |
The Royal College of Physicians
| - |
Lik Yuen Chan | M | 55 |
The Royal College of Physicians
| 29 years |
Ian Gourley | M | - |
The Royal College of Physicians
| - |
Mark White | M | 57 |
The Royal College of Physicians
| - |
Christopher Burton | M | - |
The Royal College of Physicians
| - |
Andy Billinton | M | - |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 2 years |
Huck Joo Tan | M | 56 |
The Royal College of Physicians
| 27 years |
Miles Gerson | M | - |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 3 years |
Arvind Balakrishna Kasaragod | M | - |
The Royal College of Physicians
| - |
Bipin Mistry | M | - |
The Royal College of Physicians
| - |
Robbie Woodman | M | 47 |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | - |
Ravi Rao | M | 55 |
The Royal College of Physicians
| - |
Ashish Soman | M | - |
The Royal College of Physicians
| - |
Edwin Tucker | M | 52 |
The Royal College of Physicians
| - |
Dominic Smethurst | M | 50 |
The Royal College of Physicians
| - |
Mary Canning | M | 50 |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 2 years |
Omar Khwaja | M | 54 |
The Royal College of Physicians
| 25 years |
Chun Kwan Chow | M | 69 |
The Royal College of Physicians
| 39 years |
Wai Ming Lam | M | 66 |
The Royal College of Physicians
| 35 years |
John Cullity | M | - |
The Royal College of Physicians
| - |
Seng Weng Wong | M | - |
The Royal College of Physicians
| - |
Jan Thirkettle | M | - |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 3 years |
Alexander Macrae | M | 61 |
The Royal College of Physicians
| - |
Michael Burgess | M | 61 |
The Royal College of Physicians
| - |
Rudolf Kwan | M | 71 |
The Royal College of Physicians
| - |
Suan Yew Lee | M | 91 |
The Royal College of Physicians
| - |
Ken Cunningham Cunningham | M | 71 |
The Royal College of Physicians
| - |
John Bonnar | M | - |
The Royal College of Physicians
| - |
Harry Solomon | M | 87 |
The Royal College of Physicians
| - |
Joey Mason | M | - |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
Richard Fuller | M | - |
The Royal College of Physicians
| - |
Ka Wah Hui | M | 60 |
The Royal College of Physicians
| - |
Michael Howard Jones | M | 59 |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 6 years |
David Shapiro | M | 69 |
The Royal College of Physicians
| - |
Herman Waldmann | M | - |
The Royal College of Physicians
| - |
Ik King Tiong | M | 74 |
The Royal College of Physicians
| 47 years |
Richard Mason | M | - |
The Royal College of Physicians
| - |
Paul Blake | M | 76 |
The Royal College of Physicians
| - |
Cheok Peng Lim | M | 77 |
The Royal College of Physicians
| 47 years |
Henry Y. Pan | M | 77 |
The Royal College of Physicians
| - |
Helen Torley | M | 61 |
The Royal College of Physicians
| - |
Freda Lewis-Hall | M | 69 |
The Royal College of Physicians
| - |
Lesley Russell | M | 63 |
The Royal College of Physicians
| 37 years |
Andrew Allen | M | 57 |
The Royal College of Physicians
| - |
Frank Armstrong | M | 67 |
The Royal College of Physicians
| 40 years |
Colin Broom | M | 68 |
The Royal College of Physicians
| - |
Hamish Alan Cameron | M | 70 |
The Royal College of Physicians
| - |
Peter Dewis | M | - |
The Royal College of Physicians
| - |
Siew Mun Chu | M | 81 |
The Royal College of Physicians
| 50 years |
Simon Long | M | - |
The Royal College of Physicians
| - |
Michael McDonald | M | - |
The Royal College of Physicians
| - |
Hilary McElwaine-Johnn | M | - |
The Royal College of Physicians
| - |
Preetinder Singh Joshi | M | 75 |
The Royal College of Physicians
| 46 years |
Kim Chan Koh | M | - |
The Royal College of Physicians
| - |
Stephen D. Wise | M | - |
The Royal College of Physicians
| - |
Akshay Vaishnaw | M | 61 |
The Royal College of Physicians
| - |
Ramesh Kancharla | M | 63 |
The Royal College of Physicians
| - |
Kim Heung Tan | M | 62 |
The Royal College of Physicians
| 35 years |
Caroline Dumas | M | - |
The Royal College of Physicians
| - |
Alan Suggett | M | 80 |
The Royal College of Physicians
| - |
Felicity Gabbay | M | 72 |
The Royal College of Physicians
| - |
Ena Prossner | M | 58 |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
Samuel N. Marcus | M | - |
The Royal College of Physicians
| - |
Emiko Terasaki | M | - |
The Royal College of Physicians
| 25 years |
Swee Huat Phua | M | 70 |
The Royal College of Physicians
| - |
Mehmood Khan | M | 66 |
The Royal College of Physicians
| - |
Dawn Viveash | M | 68 |
The Royal College of Physicians
| - |
Leo Kearns | M | - |
The Royal College of Physicians
| - |
Edwin Graham Meek | M | 76 |
The Royal College of Physicians
| - |
Keng Hwang Teh | M | 71 |
The Royal College of Physicians
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Elmar Schnee | M | 65 | 1 years | |
Peter Allen | M | 68 | 9 years | |
John Hartup | M | 73 | 9 years | |
Sharon Curran | F | 56 | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 97 | 97.00% |
Ireland | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alan Keith Boyd
- Personal Network